ArticleWorld journal of gastroenterology2015
Doctor communication quality and Friends' attitudes influence complementary medicine use in inflammatory bowel disease.
Article in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Complementary and alternative medicine mention and recommendations in inflammatory bowel disease guidelines: systematic review and assessment using AGREE II.BMC complementary medicine and therapies · 2023Pooled it
- Use of complementary therapies is associated with expectations of treatment effectiveness among persons with multiple sclerosis.BMJ neurology open · 2026Article
- Social Listening as a Tool to Understand Nutrition-Related Information Needs: A Case Study in Inflammatory Bowel Disease.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2025Article
- Natural Products for the Treatment of Irritable Bowel Syndrome.Gastroenterology & hepatology · 2025Article
- Crohn's Disease Phenotypes and Associations With Comorbidities, Surgery Risk, Medications and Nonmedication Approaches: The MAGIC in IMAGINE Study.Inflammatory bowel diseases · 2025Observational
- Motivations behind complementary and alternative medicine use in patients with Crohn's disease and ulcerative colitis.Journal of the Canadian Association of Gastroenterology · 2024Article
- Use of Complementary and Alternative Therapies in People with Inflammatory Bowel Disease.International journal of environmental research and public health · 2024Article
- Cannabis Use in Patients With Inflammatory Bowel Disease Following Legalization of Cannabis in Canada.Crohn's & colitis 360 · 2024Article
- Obstacles to Medication Adherence for Patients with Inflammatory Bowel Disease: A Qualitative Study in East China.Patient preference and adherence · 2024Article
- Health Communication Research Informs Inflammatory Bowel Disease Practice and Research: A Narrative Review.Crohn's & colitis 360 · 2023Article
- A primer on common supplements and dietary measures used by patients with inflammatory bowel disease.Therapeutic advances in chronic disease · 2023Review
- Dietary management of adults with IBD - the emerging role of dietary therapy.Nature reviews. Gastroenterology & hepatology · 2022Review
- Innovative, complementary and alternative therapy in inflammatory bowel diseases: A broad 2020s update.Frontiers in gastroenterology (Lausanne, Switzerland) · 2022Review
- Facilitators and barriers to the clinical administration of herbal medicine in Ghana: a qualitative study.BMC complementary medicine and therapies · 2021Article
- Medication adherence and complementary therapy usage in inflammatory bowel disease patients during the coronavirus disease 2019 pandemic.JGH open : an open access journal of gastroenterology and hepatology · 2021Article
- Assessment of patient-centered outcomes (PROs) in inflammatory bowel disease (IBD): a multicenter survey preceding a cross-disciplinary (functional) consensus.Health and quality of life outcomes · 2020Observational
- Changes in prevalence and perception of complementary and alternative medicine use in Korean inflammatory bowel disease patients: results of an 8-year follow-up survey.Intestinal research · 2020Article
- Complementary and alternative medications in the management of inflammatory bowel disease.Therapeutic advances in gastroenterology · 2020Review
- Optimizing the multidimensional aspects of the patient-physician relationship in the management of inflammatory bowel disease.Intestinal research · 2018Article
- Non-pharmacological therapies for inflammatory bowel disease: Recommendations for self-care and physician guidance.World journal of gastroenterology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo examine the frequency of regular complementary and alternative therapy (CAM) use in three Australian cohorts of contrasting care setting and geography, and identify independent attitudinal and psychological predictors of CAM use across all cohorts.
methodsA cross sectional questionnaire was administered to inflammatory bowel disease (IBD) patients in 3 separate cohorts which differed by geographical region and care setting. Demographics and frequency of regular CAM use were assessed, along with attitudes towards IBD medication and psychological parameters such as anxiety, depression, personality traits and quality of life (QOL), and compared across cohorts. Independent attitudinal and psychological predictors of CAM use were determined using binary logistic regression analysis.
resultsIn 473 respondents (mean age 50.3 years, 60.2% female) regular CAM use was reported by 45.4%, and did not vary between cohorts. Only 54.1% of users disclosed CAM use to their doctor. Independent predictors of CAM use which confirm those reported previously were: covert conventional medication dose reduction (P < 0.001), seeking psychological treatment (P < 0.001), adverse effects of conventional medication (P = 0.043), and higher QOL (P < 0.001). Newly identified predictors were CAM use by family or friends (P < 0.001), dissatisfaction with patient-doctor communication (P < 0.001), and lower depression scores (P < 0.001).
conclusionIn addition to previously identified predictors of CAM use, these data show that physician attention to communication and the patient-doctor relationship is important as these factors influence CAM use. Patient reluctance to discuss CAM with physicians may promote greater reliance on social contacts to influence CAM decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.